Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
July 23, 2024
Approach to the Patient: New Era Emerges for Craniopharyngioma Management
Annabelle G Hayes, Benjamin Jonker, Christina Teng, et al.
Internal Medicine Journal
|
June 28, 2022
Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy
Christina Teng, Elodie Chiarovano, David Tighe, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer
Christina Teng, Stephanie E Reuter, Prunella L Blinman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 6, 2014
AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor
Shiuan Chen, Dujin Zhou, Li-Yu Hsin, et al.
Chemico-Biological Interactions
|
April 9, 2013
Bisphenol A affects androgen receptor function via multiple mechanisms
Christina Teng, Bonnie Goodwin, Keith Shockley, et al.
JNCI Cancer Spectrum
|
March 28, 2025
Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
Journal of Translational Medicine
|
January 9, 2025
A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Chenfei Zhou, Bin Wang, Christina Teng, et al.
Cancers
|
May 4, 2026
Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials
Jessie Nguyen, Udit Nindra, Joanne Tang, et al.
JNCI Cancer Spectrum
|
November 10, 2025
Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
JCO Oncology Practice
|
November 3, 2025
Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
The Journal of Clinical Endocrinology and Metabolism
|
July 23, 2024
Approach to the Patient: New Era Emerges for Craniopharyngioma Management
Annabelle G Hayes, Benjamin Jonker, Christina Teng, et al.
Internal Medicine Journal
|
June 28, 2022
Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy
Christina Teng, Elodie Chiarovano, David Tighe, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2020
Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer
Christina Teng, Stephanie E Reuter, Prunella L Blinman, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
February 6, 2014
AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor
Shiuan Chen, Dujin Zhou, Li-Yu Hsin, et al.
Chemico-Biological Interactions
|
April 9, 2013
Bisphenol A affects androgen receptor function via multiple mechanisms
Christina Teng, Bonnie Goodwin, Keith Shockley, et al.
JNCI Cancer Spectrum
|
March 28, 2025
Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
Journal of Translational Medicine
|
January 9, 2025
A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors
Chenfei Zhou, Bin Wang, Christina Teng, et al.
Cancers
|
May 4, 2026
Measuring What Matters: RECIST Response Does Not Predict HRQoL in Early-Phase Clinical Trials
Jessie Nguyen, Udit Nindra, Joanne Tang, et al.
JNCI Cancer Spectrum
|
November 10, 2025
Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
JCO Oncology Practice
|
November 3, 2025
Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study
Udit Nindra, Joanne Tang, Jun Hee Hong, et al.
Page
of 3